OCREVUS®

OCREVUS® (Ocrelizumab) is an immunosuppressive drug used in the treatment of Relapsing and Primary Progressive Multiple Sclerosis.

OCREVUS® is manufactured by Genentech.

Administration and Dosage:

Administration of OCREVUS® is a biweekly intravenous infusion for 2 doses followed by a 6 month maintenance dose.

Indication:

OCREVUS® is indicated to treat:

  • Multiple Sclerosis

Common Side Effects:

The more common side effects of OCREVUS® include infusion reactions and infections.

More information:

Please read the full Prescribing Information for OCREVUS® and discuss any questions you have with your doctor.

HAVE QUESTIONS?

We are happy to help!
Name